Revive Therapeutics Applies to FDA for Orphan Drug Designation …

TORONTO, ONTARIO–(Marketwired – Sept. 27, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of autoimmune hepatitis (“AIH”), a rare liver disease.

“This orphan drug designation application is an important first step in the commercial development process of cannabidiol for the potential treatment of autoimmune hepatitis,” said Craig Leon, Chief Executive Officer of Revive. “We are focused on advancing the research of novel therapies that target the endocannabinoid system, such as the CB1 and CB2 endocannabinoid receptors, and further strengthen our product pipeline with potentially safer and effective treatments for various liver diseases.”

Under the Orphan Drug

... read more at: